Mirum Pharmaceuticals, Inc.
MIRM
$43.45
$0.912.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 80.76% | 112.14% | 128.34% | 133.90% | 141.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.76% | 112.14% | 128.34% | 133.90% | 141.85% |
| Cost of Revenue | 73.56% | 216.38% | 281.46% | 301.17% | 280.14% |
| Gross Profit | 83.19% | 88.77% | 97.87% | 103.01% | 115.40% |
| SG&A Expenses | 38.62% | 51.85% | 58.32% | 61.03% | 63.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.64% | 57.76% | 59.15% | 50.17% | 41.89% |
| Operating Income | 19.74% | 13.33% | 8.47% | 13.66% | 16.82% |
| Income Before Tax | 46.49% | 39.99% | 38.83% | -16.06% | -14.33% |
| Income Tax Expenses | 3.94% | 102.10% | 158.66% | 122.75% | 115.47% |
| Earnings from Continuing Operations | 46.18% | 39.21% | 38.08% | -22.74% | -20.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.18% | 39.21% | 38.08% | -22.74% | -20.45% |
| EBIT | 19.74% | 13.33% | 8.47% | 13.66% | 16.82% |
| EBITDA | 34.93% | 30.03% | 21.79% | 23.13% | 23.17% |
| EPS Basic | 55.62% | 49.23% | 48.23% | -5.14% | -2.02% |
| Normalized Basic EPS | -9.66% | 67.85% | 64.14% | 64.21% | 61.08% |
| EPS Diluted | 55.66% | 49.34% | 48.34% | -4.70% | -1.63% |
| Normalized Diluted EPS | -9.66% | 67.80% | 64.09% | 64.17% | 61.04% |
| Average Basic Shares Outstanding | 20.09% | 21.30% | 21.86% | 20.50% | 19.31% |
| Average Diluted Shares Outstanding | 20.09% | 21.19% | 21.74% | 20.36% | 19.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |